Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868582 | 0.86 | RBP4 (0.39) | RBP4DDB1CRBNESR2ADORA1 | |
| SCHEMBL17868644 | 0.86 | RBP4 (0.39) | RBP4DDB1CRBNESR2ADORA1 | |
| SCHEMBL30993458 | 0.85 | USP2 (0.42) | USP2SMN1; SMN2RECQLRBP4MTOR | |
| SCHEMBL17868680 | 0.83 | ESR2 (0.40) | RBP4DDB1CRBNESR2ADORA1 | |
| SCHEMBL17868643 | 0.82 | RBP4 (0.37) | USP2SMN1; SMN2RECQLRBP4DDB1 | |
| SCHEMBL4762504 | 0.79 | DPP4 (0.44) | RBP4DDB1CRBNESR2ADORA1 | |
| SCHEMBL34470985 | 0.78 | MAPK1 (0.48) | RBP4 | |
| SCHEMBL17868654 | 0.76 | ESR2 (0.46) | USP2SMN1; SMN2ESR2ADORA1NR1H2 | |
| SCHEMBL14971269 | 0.76 | ESR2 (0.43) | ESR2ADORA1NR1H2MAPTIGF1R | |
| SCHEMBL10296218 | 0.76 | ESR2 (0.43) | USP2SMN1; SMN2ESR2ADORA1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190077800-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20190077800-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-10093669-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9518057-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518057-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518057-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077800-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | USP2 1816/4885SMN1; SMN2 4722/4885RECQL 617/4885 |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | USP2 1816/4885SMN1; SMN2 4722/4885RECQL 617/4885 |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | USP2 1816/4885SMN1; SMN2 4722/4885RECQL 617/4885 |
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | USP2 1816/4885SMN1; SMN2 4722/4885RECQL 617/4885 |
| US-10093669-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | USP2 1816/4885SMN1; SMN2 4722/4885RECQL 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.